Keyphrases
Atypical Antipsychotics
100%
5-HT1A
100%
Novel Object Recognition
100%
Serotonin 5-HT
100%
Phencyclidine
100%
Serotonin 2A Receptor (5-HT2AR)
100%
Dopamine D2 Receptor (DRD2)
100%
Drug Effects
100%
Agonism
100%
Receptor Antagonism
100%
Schizophrenia
28%
Antagonism
28%
Cognitive Impairment
28%
Typical Antipsychotics
28%
Antipsychotics
28%
5-HT2A Agonists
28%
Haloperidol
28%
N-methyl-D-aspartate Receptor (NMDAR)
14%
5-HT1A Partial Agonist
14%
Lurasidone
14%
Subchronic Administration
14%
Effective Dose
14%
Efflux
14%
Receptor Antagonist
14%
Signaling Cascades
14%
Prevention Model
14%
Pimavanserin
14%
5-HT2A Receptor
14%
Acute Administration
14%
5-HT1A Agonist
14%
Dopamine D2 Antagonist
14%
Tandospirone
14%
5-HT1A Receptor
14%
D2 Antagonist
14%
Triple Combination
14%
Inverse Agonism
14%
Neuroscience
Serotonin
100%
Atypical Antipsychotic
100%
Phencyclidine
100%
Dopamine Receptor D2
100%
Antipsychotic
100%
Cognitive Disorders
66%
D2 Antagonists
66%
5-HT2A Receptor
66%
Inverse Agonist
66%
Typical Antipsychotic
66%
Haloperidol
66%
In Vivo
33%
5-HT1A Agonists
33%
Lurasidone
33%
5-HT1A Receptor
33%
Pimavanserin
33%
Agonist
33%
Receptor Antagonist
33%
Dextro Aspartic Acid
33%
Inverse Agonism
33%
Tandospirone
33%
Pharmacology, Toxicology and Pharmaceutical Science
Atypical Antipsychotics
100%
Dopamine Receptor D2
100%
Phencyclidine
100%
Serotonin
100%
Receptor
75%
Cognitive Defect
50%
Inverse Agonist
50%
Typical Antipsychotic
50%
4 (para chlorophenyl) 1 [3 (para fluorobenzoyl)propyl] 4 piperidinol
50%
Lurasidone
25%
Effusion
25%
Pimavanserin
25%
Partial Agonist
25%
Serotonin 1A Agonist
25%
Tandospirone
25%
Dopamine 2 Receptor Blocking Agent
25%
Dextro Aspartic Acid
25%
Receptor Antagonist
25%